Complexing Behaviour and Antifungal Activity of N-[(1E)-1-(1H-Benzimidazol-2-yl)ethylidene]morpholine-4-carbothiohydrazide and Related Ligand with Metal Ions
The coordination complexes of bivalent metal ions with N-[(1E)-1-(1H-Benzimidazol-2-yl)ethylidene]morpholine-4-carbothiohydrazide (H2bmctz, H2L-1) and N-[(1E)-1-(1H-Benzimidazol-2-yl)(phenyl)methylidene] morpholine-4-carbothiohydrazide (H2bpmctz, H2L-2) were prepared and their neutral, monoanionic, and dianionic forms of ligands of compositions [M(H2L)X2] (M= , , , , , or , X=Cl？ or Br？, and H2L=H2L-1 or H2L-2), [M(HL)2]nH2O where (M= , , , , or , H2L=H2L-1 or H2L-2, and n = 0 or 2), and [MLB]nB (M= , , , , or , B=H2O, Py, or -pic, n = 0 and n = 1 if B=H2O for Ni(II) and H2L=H2L-1 or H2L-2) have been characterised by magnetic susceptibility measurements, electrical conductance values, and spectral properties. The magnetic moment value of [M(HL2)] (M= , , or ) type complexes is consistent with high spin octahedral structure while those of [M(H2L)X2] (M= , , , , or , X=Cl？ or Br？) possess five coordinated trigonal bipyramidal geometry. The adduct complexes [MLB]·nB (M= , or , B=H2O, Py, or -pic) are four coordinated planar and those of and complexes [MLB], (H2L=H2L-1 or H2L-2, B=H2O, Py or -pic) are tetrahedral. These ligands have been suggested to coordinate as tridentate (N N S) donor molecule in complexes of type [M(H2L)X2], [M(HL)2], and [MLB]. The antifungal activity of ligands and some of their metal complexes were studied and it was observed that metal complexes show higher activity than free ligand. 1. Introduction Preparation and structural aspects of various metal ions with a number of benzimidazole derivatives have been reported by one of us and a number of chemists [1–10]. Medicinal properties of benzimidazole derivatives have established that benzimidazoles have privileged substructures for drug design [11, 12]. The most vital benzimidazole derivatives is N-ribosyl-5,6-dimethylbenzimidazole which is axial ligand in vitamin B12 possessing selective neuropeptide YY1 receptor antagonists [13], 5-lipo xyginase inhibitor [14] and poly (ADP-ribose) polymerase inhibitors [14]. Benzimidazole derivatives are of immense interest because of their wide spectrum of biological activity such as anticancer [15], antiviral [16, 17], antihistaminic [18], antifungal [19], anti-HBV [20], antibacterial [21], antitumoral [22], antiparasitic [22], antihelminitic [23], anti-inflammatory, local analgesic, hypotensive [24], antiulcer [25], and neuro leptic cardiotonic [26]. Extensive biochemical and pharmacological studies have confirmed that various benzimidazole derivatives are effective against various strains of microorganisms [25]. The wide ranging biological and
References
[1]
S. O. Podunavac-Kuzmanovic, D. M. Cvetkovic, and L. S. Vojinovic, “Synthesis, physico-chemical characterization and biological activity of 2-aminobenzimidazole complexes with different metal ions,” APTEFF, vol. 35, pp. 239–246, 2004.
[2]
S. P. Ghosh and L. K. Mishra, “Complex compounds of iron(II, III) with 2-(2′-pyridyl)benzimidazol,” Inorganica Chimica Acta, vol. 7, pp. 545–548, 1973.
[3]
S. P. Ghosh, P. Bhattacharjee, L. Dubey, and L. K. Mishra, “Complexes of some platinum metals with imidazole and benzimidazole,” Journal of the Indian Chemical Society, vol. 52, pp. 230–235, 1974.
[4]
S. K. Gupta and L. K. Mishra, “Oxo-vanadium(IV) complexes with 2-(o-hydroxyphenyl)benzimidazole and related ligands,” Journal of Inorganic and Nuclear Chemistry, vol. 41, no. 6, pp. 890–891, 1979.
[5]
K. K. R. Anil and L. K. Mishra, “Complexes of Rh(III) and Pd(II) with N-vinylimidazole,” Journal of the Indian Chemical Society, vol. 64, pp. 503–505, 1987.
[6]
M. Bala, K. Ahmad, S. Sharma, and L. K. Mishra, “Preparation, characterisation and antifungal activity of 1E-1-(1H-benzimidazol-2-yl)-N-hydroxy ethanimine and 1E-1-(1H-benzimidazol-2-yl)-N-hydroxy-1-phenyl methanimine withCo(II), Ni(II), Cu(II), Zn(II) and Cd(II),” IOSR Journal of Applied Chemistry, vol. 3, no. 2, pp. 21–29, 2012.
[7]
M. Bala and L. K. Mishra, “Synthesis, characterisation and anti amoebic activity of 1E-1-(1H-benzimidazole-2-yl)-N-hydroxy ethanimine and 1E-1-(1H-benzimidazole-2-yl)-N-hydroxy-1-phenyl methanimine with oxovanadium (IV), Mn(II), Fe(II),” International Journal of Emerging Technologies in Computationaland Applied Sciences, vol. 4, no. 4, pp. 347–353, 2013.
[8]
A. K. Tripathi and P. Mathur, “A binuclear iron(III) complex of N,N,N′,N′-tetrakis[(2-benzimidazolyl)]-1,2-ethanediamine,” Journal of the Indian Chemical Society, vol. 70, p. 991, 1993.
[9]
S. Das, S. Malik, and B. Jain, “Synthesis and spectroscopic characterization of metal complexes of rabeprazole drug,” Journal of Indian Council of Chemist, vol. 27, no. 2, pp. 177–179, 2010.
[10]
M. R. Maurya, S. Sikarwar, T. Joseph, P. Manikandan, and S. B. Halligudi, “Synthesis, characterization and catalytic potentials of polymer anchored copper(II), oxovanadium(IV) and dioxomolybdenum(VI) complexes of 2-(α-hydroxymethyl)benzimidazole,” Reactive and Functional Polymers, vol. 63, no. 1, pp. 71–83, 2005.
[11]
B. E. Evans, K. E. Rittle, M. G. Bock et al., “Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists,” Journal of Medicinal Chemistry, vol. 31, no. 12, pp. 2235–2246, 1988.
[12]
A. A. Spasov, I. N. Yozhitsa, L. I. Bugaeva, and V. A. Anisimova, “Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties (a review),” Pharmaceutical Chemistry Journal, vol. 33, no. 5, pp. 232–243, 1999.
[13]
H. A. Barker, R. D. Smyth, H. Weissbach, J. I. Toohey, J. N. Ladd, and B. E. Volcani, “Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5, 6-dimethylbenzimidazole,” The Journal of Biological Chemistry, vol. 235, pp. 480–488, 1960.
[14]
H. Nakano, T. Inoue, N. Kawaohaki et al., “Synthesis and biological activities of novel antiallergic agents with 5-lipoxygenase inhibiting action,” Bioorganic & Medicinal Chemistry, vol. 8, no. 2, pp. 373–380, 2000.
[15]
K. Star？evi？, M. Kralj, K. Ester et al., “Synthesis, antiviral and antitumor activity of 2-substituted-5-amidino-benzimidazoles,” Bioorganic & Medicinal Chemistry, vol. 15, no. 13, pp. 4419–4426, 2007.
[16]
G.-F. Wang, L.-P. Shia, Y.-D. Ren et al., “Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro,” Antiviral Research, vol. 83, no. 2, pp. 186–190, 2009.
[17]
Y.-F. Li, G.-F. Wang, P.-L. He et al., “Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives,” Journal of Medicinal Chemistry, vol. 49, no. 15, pp. 4790–4794, 2006.
[18]
K. Ishihara, T. Ichikawa, Y. Komuro, S. Ohara, and K. Hotta, “Effect on gastric mucus of the proton pump inhibitor leminoprazole and its cytoprotective action against ethanol-induced gastric injury in rats,” Drug Research, vol. 44, no. 7, pp. 827–830, 1994.
[19]
W. A. Maxwell and G. Brody, “Antifungal activity of selected benzimidazole compounds,” Applied Microbiology, vol. 21, no. 5, pp. 944–945, 1971.
[20]
P. L. Beaulieu, M. B？s , Y. Bousquet et al., “Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 1, pp. 119–124, 2004.
[21]
P. T. M. Nguyen, J. D. Baldeck, J. Olsson, and R. E. Marquis, “Antimicrobial actions of benzimidazoles against oral streptococci,” Oral Microbiology and Immunology, vol. 20, no. 2, pp. 93–100, 2005.
[22]
M. Boiani and M. Gonzalez, “Imidazole and benzimidazole derivatives as chemotherapeutic agents,” Mini-Reviews in Medicinal Chemistry, vol. 5, no. 4, pp. 409–424, 2005.
[23]
H. Kü？ükbay, R. Durmaz, E. Orhan, and S. Günal, “Synthesis, antibacterial and antifungal activities of electron-rich olefins derived benzimidazole compounds,” Il Farmaco, vol. 58, no. 6, pp. 431–437, 2003.
[24]
V. K. Pandey, M. Upadhyay, M. Upadhyay, V. D. Gupta, and M. Tandon, “Benzimidazolyl quinolinyl mercaptotriazoles as potential antimicrobial and antiviral agents,” Acta Pharmaceutica, vol. 55, no. 1, pp. 47–56, 2005.
[25]
D. Y. Graham, A. McCullough, M. Sklar et al., “Omeprazole versus placebo in duodenal ulcer healing. The United States experience,” Digestive Diseases and Sciences, vol. 35, no. 1, pp. 66–72, 1990.
[26]
P. A. Janssen and F. T. Allewijn, “Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. II. Kinetic study of the distribution of pimozide and metabolites in brain, liver, and blood of the Wistar rat,” Drug Research, vol. 18, no. 3, pp. 279–282, 1968.
[27]
B. Halliwell and J. M. C. Gutteridge, “Role of free radicals and catalytic metal ions in human disease: an overview,” Methods in Enzymology, vol. 186, pp. 1–85, 1990.
[28]
W. N. Lipscomb and N. Str？ter, “Recent advances in zinc enzymology,” Chemical Reviews, vol. 96, no. 7, pp. 2375–2434, 1996.
[29]
D. R. Richardson, “Iron chelators as therapeutic agents for the treatment of cancer,” Critical Reviews in Oncology/Hematology, vol. 42, no. 3, pp. 267–281, 2002.
[30]
M. E. Maguire and J. A. Cowan, “Magnesium chemistry and biochemistry,” BioMetals, vol. 15, no. 3, pp. 203–210, 2002.
[31]
R. R. Crichton, Biological Inorganic Chemistry: An Introduction, Elsevier, Amsterdam, The Netherlands, 2008.
[32]
M. Sugiyama, “Role of cellular antioxidants in metal-induced damage,” Cell Biology and Toxicology, vol. 10, no. 1, pp. 1–22, 1994.
[33]
K. Ramaiah, J. S. Grossert, D. L. Hooper, P. K. Dubey, and J. Ramanatham, “Studies on synthesis of 2-acetylbenzimidazole and related benzimidazole derivatives,” Journal of the Indian Chemical Society, vol. 76, no. 3, pp. 140–144, 1999.
[34]
L. F. Audrieth, E. S. Scott, and P. S. Kippur, “Hydrazine derivatives of the carbonic and thiocarbonic acids. I. The preparation and properties of thiocarbohydrazide,” Journal of Organic Chemistry, vol. 19, no. 5, pp. 733–741, 1954.
[35]
M. A. Phillips, “CCCXVII.—the formation of 2-substituted benziminazoles,” Journal of the Chemical Society, pp. 2393–2399, 1928.
[36]
W. J. Geary, “The use of conductivity measurements in organic solvents for the characterisation of coordination compounds,” Coordination Chemistry Reviews, vol. 7, no. 1, pp. 81–122, 1970.
[37]
B. N. Figgis and J. Lewis, “The magnetic properties of transition metal complexes,” in Progress in Inorganic Chemistry, vol. 6, pp. 37–239, John Wiley & Sons, New York, NY, USA, 1964.
[38]
R. C. Stoufer, D. W. Smith, E. A. Clevenger, and T. E. Norris, “Complexes of cobalt(II). I. On the anomalous magnetic behavior of some six-coordinate cobalt(II) complexes,” Inorganic Chemistry, vol. 5, no. 7, pp. 1167–1171, 1966.
[39]
A. B. P. Lever, Inorganic Electronic Spectroscopy, Elsevier, New York, NY, USA, 1968.
[40]
M. K. Das, M. Nath, and J. J. Zuckerman, “Di- and triorganotin(IV) derivatives of N,N-substituted hydroxylamines,” Inorganica Chimica Acta, vol. 71, pp. 49–59, 1983.
[41]
M. R. Gajendragad and U. C. Agrawala, “Complexing behaviour of 5-amino-1,3,4-thiazole-2-thiol. II. Complexes of Ni(II), Rh(I), Pd(II), Pt(II), Au(III) and Cu(II),” Bulletin of the Chemical Society of Japan, vol. 48, no. 3, pp. 1024–1029, 1975.
[42]
K. Nakamoto, Infrared and Raman Spectra of Inorganic and Complex Compounds, John Wiley & Sons, New York, NY, USA, 1978.
[43]
A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, “Antibiotic susceptibility testing by a standardized single disk method,” American Journal of Clinical Pathology, vol. 45, no. 4, pp. 493–496, 1966.
[44]
F. Cavanagh, Analytical Microbiology, Academic Press, New York, NY, USA, 1963.
[45]
Y. Anjaneyulu, L. N. Murthy, and R. P. Rao, “Preparation, characterization and antimicrobial activity studies on some ternary complexes of Cu(II) with acetylacetone and various salicylic acids,” Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry, vol. 16, no. 2, pp. 257–272, 1986.
[46]
T. J. Franklin and G. A. Snow, “Penetrating the defences,” in Biochemistry of Antimicrobial Action, Chapman and Hall, London, UK, 1971.
